د داد،

2010 Prescrire Information Awards

The Information Awards focus on the quality of the information provided to *Prescrire* by the pharmaceutical companies whose products we examined in the New Products section of our French edition during the previous year (in 2010: issues 315 to 326).

Prescrire's reviews dealing with new drugs and indications are based on a thorough literature search for documents relating to the drug's pre-approval assessment, especially clinical trial reports.

In addition to textbooks and bibliographic databases, editors search the websites of drug regulatory agencies, health economics institutions, health technology assessment agencies and other institutions specialising in the relevant therapeutic field. We also search other independent journals belonging to the International Society of Drug Bulletins (ISDB), and any independent institutions that have evaluated the drug in question. We often request documents from drug regulatory agencies.

Assessing drug company transparency. We also request relevant information from the companies that market each drug we analyse in France, to ensure that we take into account all data, including unpublished data, used to justify marketing approval or to modify an existing marketing authorisation. Such unpublished data (for example, expert reviews) may be held by the drug regulatory agency that examined the application and by the company that obtained marketing authorisation.

As with the other *Prescrire* Awards, a systematic and totally independent process is used to grant the Information Awards (rules available on our website, at www.english.prescrire.org).

Rewarding accountable companies. Some drug companies respond to our requests for information in a timely manner and provide us with thorough and relevant data, including unpublished data. These companies are mentioned on the Honours List.

The companies rated as "Outstanding" provided us with exhaustive and detailed information without delay, sometimes without being asked.

What do unhelpful companies have to hide?

Other drug companies either fail to respond to our requests for information or provide only limited data. They tend

Honours list (in alphabetical order)



- Outstanding : Janssen-Cilag, Nycomed, Sanofi Pasteur MSD
- Followed by: CSL Behring, Galderma, GlaxoSmithKline and Lundbeck

Red cards (in alphabetical order)

 Allergan, Genévrier, Ipsen, Lilly, Meda Pharma, Menarini, Pfizer, Pierre Fabre Médicament, Roche, Sanofi Aventis, Servier

to delay their response as long as possible, i.e. only after publication of the opinion of the French Transparency Committee (that assesses the comparative effectiveness of new drugs and provides advice on drug reimbursement), or of the price in the Journal Officiel or after the launch of their advertising campaign. They may also omit the most relevant data, claiming to be too busy, that the administrative services are too slow or that the clinical data are confidential. Other companies withhold information as a kind of retaliation because they did not like one of our earlier product reviews.

Few pharmaceutical companies persistently withhold information. For patients' sake, we hope that refusal of transparency or lack of respect for the independence of the editorial staff of *Prescrire* and its subscribers do not constitute reasons for withholding information.

"Red cards" for withholding information are a way of highlighting persistent shortcomings in the provision of information by certain drug companies and a way of encouraging more openness.

Take into account drug company transparency when choosing a drug. A drug company's commitment to transparency is the fifth factor to be taken into account when choosing a drug, after efficacy, safety, convenience and price.

When two drugs are otherwise indistinguishable, then it is in patients' and healthcare professionals' best interests to prefer the product manufactured by the company that has least to hide.

©Prescrire

Whenever we examine a new drug, the article is accompanied by one of four pictograms rating the transparency of the company concerned for their response to our requests for information about their product (see this issue p. 68).







